LAUSR

Ibrutinib treatment for 72 hours at 5 doses in MCL lines, IR, ibrutinib resistance. IC50s were calculated using GraphPad Prism software. (B) CCK8 assay showing the effects of ABT199, AZD8055 and the combination of ABT-199 with AZD8055 on cell viability of SP49, Jeko-1 and HBL-2 ibrutinib sensitive and IR cells. (C) CCK8 assay showing the effects of ABT-199, BEZ235 and the combination of ABT-199 with BEZ235 on cell viability of SP49, Jeko-1 and HBL-2 ibrutinib sensitive and IR cells. (D) CCK8 assay showing the effects of ABT-199, AZD8055 or BEZ235 and the combination of ABT-199 with AZD8055 or with BEZ235 on cell viability of Maver-1 and Granta-519 cells. Fig S2. (A) CCK8 assay showing the effects of ABT-199, AZD8055 and the combination of ABT-199 with AZD8055 for 48h on cell viability of primary MCL patient samples (Pt MCL3-8). (B) CCK8 assay showing the effects of ABT-199, BEZ235 and the combination of ABT-199 with BEZ235 for 48h on cell viability of primary MCL patient samples (Pt MCL3-8). (C) Western blots showing the changes of MCL1, BCL2 and BCL-xL protein levels after BEZ235 and AZD8055 treatment in ibrutinib sensitive and IR Jeko-1 and HBL-2 cells. (D) Western blots showing the changes of MCL1, BCL2 and BCL-xL protein levels after ABT-199 treatment in ibrutinib sensitive and IR SP49, Jeko-1 and HBL-2 cells. (E) Western blots showing the changes of MCL1, BCL2 and BCL-xL protein levels after ABT-199, AZD8055 or BEZ235 and combination of ABT-199 with AZD8055 or with BEZ235 in ibrutinib sensitive and IR Jeko-1 and HBL-2 cells.